Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2013 Apr 17;288(22):16110–16116. doi: 10.1074/jbc.M113.466144

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2013 by The American Society for Biochemistry and Molecular Biology, Inc.

PMC Copyright notice

FIGURE 3. — Activin A activates target genes in pluripotent lines knocked down for macro histone variants. A, FACS analysis of expression of OCT4 and CXCR4 in ESCs before (day 0) and after 3 days (day 3) of treatment with Activin A. B, mRNA levels determined by qPCR of pluripotency and differentiation genes in ESCs before (d0) and after 3 days (d3) of Activin A treatment. mRNA levels were normalized to GAPDH. Graphs show the mean ± S.D. (error bars) of triplicates. C, FACS analysis of the percentage of cells that express CXCR4 after 3 days of Activin A treatment in two lines of ES[4] control (shRD), knocked down for macroH2A.1 (shM1) or for macroH2A.2 (shM2). Graphs show the mean ± S.D. of at least four independent treatments. D, FACS analysis of the percentage of cells that express CXCR4 after 3 days of Activin A treatment in two lines of KiPS control (shRD), knocked down for macroH2A.1 (shM1) or for macroH2A.2 (shM2). Graphs show the mean ± S.D. of at least four independent treatments.